ratory data for research, was signed by all patients and/or their legal guardians.
The underlying diseases in our cohort (76 Txs in 68 patients) were as follows: 16 obstructive uropathy, 11 renal dysplasia, seven hemolytic uremic syndrome, five focal segmental glomerulosclerosis, six nephronophthisis, four congenital nephrotic syndrome, three Wilms' tumor, three acute tubular necrosis, two ARPKD, two Alport syndrome, two vasculitis, one cystinosis, one glomerulonephritis, one methylmalonic academia, one toxic, and three ECI Biopsies were performed if graft dysfunction occurred, as indicated by an increase in serum creatinine, delayed graft function, or recurrent diseases in the transplant.
GFR was calculated using the Schwartz formula at 1, 3, 6, and 12 months after Tx and yearly thereafter. The "last GFR" measurement occurred at the end of the study period, or earlier when the age of 18 years was reached, or when graft failure occurred.
Baseline GFR used for survival analysis was taken at 1 month after Tx.
Patients were stratified in two groups according to biopsy, DSA, and rejection.
We compared the renal biopsy group versus the non-biopsy group, the DSA-pos versus the DSA-neg group, and the rejectionpos versus rejection-neg group. The renal biopsy group consisted of 43 Txs, and the non-biopsy group consisted of 33 Txs. The DSA-pos group consisted of 13 Txs, and the DSA-neg group consisted of 55 Txs. In eight Txs, no blood samples were drawn for antibody testing and these were excluded from the comparison of DSA-pos and DSA-neg patients. The rejection-pos group consisted of 25 Txs, and the rejection-neg group, for which biopsies were available, consisted of 11 Txs. Seven Txs were excluded for the analysis of the rejection group, because five patients underwent transplantectomy soon after Tx and two patients showed a borderline rejection which was classified as neither pos nor neg. Txs enduring at least one rejection were considered as rejection-pos. The number of Txs with rejection is shown in the flowchart (see Figure 1 ).
The three groups were compared to characterize patients at risk of graft failure. Clinical characteristics and outcome of all groups were assessed; outcome included mean last GFR, GFR decline, and occurrence of antibody-mediated acute rejection. Biopsy tissues were assessed to distinguish between cellular and humoral rejection. The diagnosis of antibody-mediated and cellular rejection was based on the Banff recommendations. The presence of C4d deposition in biopsies was taken as a biomarker for acute humoral rejection.
All recipients received basiliximab induction therapy. Over time, three different immunosuppressive protocols were employed: The earliest protocol consisted of prednisone, cyclosporine, and mycophenolate mofetil; subsequently, cyclosporine was replaced by tacrolimus after 6 months or on clinical indication. Finally, since 2012, the "TWIST" protocol was used, including prednisone for 1 week, followed by tacrolimus and mycophenolate mofetil. Switching from mycophenolate mofetil to azathioprine occurred due to adverse gastrointestinal effects, diarrhea, or leukopenia. A switch from cyclosporine or tacrolimus to sirolimus or everolimus occurred in a few patients due to the underlying disease or side effects. The protocol for the treatment of rejection was as follows: A cellular rejection was treated with six pulses of methylprednisolone (500 mg/1.73 m 2 ); a humoral rejection was treated with methylprednisolone, plasmapheresis (7 days), IVIG, and sometimes rituximab.
ATG was only used in severe, steroid-resistant rejection episodes.
Its use declined over the years. 
| HLA class I and class II typing of donors and recipients

| Statistical analysis
Data were analyzed calculating means with SDs or medians with ranges. For testing normality, distributions of continuous variables
were analyzed using the Shapiro-Wilk test, and a visual inspection of their histograms and their skewness and kurtosis.
A parametric and a non-parametric Levene's test was used to verify the equality of variances respectively in normally and nonnormally distributed continuous variables.
To determine differences between patient groups, continuous variables were compared using an independent T test and, if nonnormally distributed, a non-parametric test. Categorical variables were compared using the chi-square test or the Fisher's exact test.
Event-free survival was estimated with the Kaplan-Meier method and was compared between groups with the log-rank test.
The primary event was defined as rejection. The censoring effect was transplantectomy or borderline rejection. Patients who did not experience rejection were censored at the end of the follow-up. The secondary event was defined as a reduction of 25% or more from the baseline GFR, measured at 1 month after Tx. The censoring effect was missing measurements of GFR. Patients who did not experience a GFR decline of 25% or more were censored at the end of the follow-up.
Statistical analyses were performed using IBM SPSS Statics 25.0.
P-values <0.05 were considered to be statistically significant.
| RE SULTS
| Clinical characteristics and biopsies
The clinical characteristics (age at Tx; post-transplant follow-up time;
donor type; number of HLA-A, HLA-B, and HLA-DR Mismatches) of the 68 patients, undergoing 76 Txs, are summarized in Table 1 , subdivided by whether a biopsy was performed (43/76) or not (33/76). For 68 of 76 Txs (concerning 61/68 patients), the DSA status was fully documented (excluded: five because of early transplantectomy and three lost to follow-up). Table 2 shows the characteristics of these 68 Txs, subdivided by the presence (13/68) or absence (55/68) of DSAs. Table 3 describes the subset of 36 Txs, for which the presence (25/36) or absence (11/36) of rejection was fully documented.
Biopsies were performed in 43 of 76 (57%) Txs, see Figure 1 .
There was a significant difference in age at Tx between patients who 
| HLA antibodies in transplanted patients
Retrospectively, HLA antibody test results were available for 53%, 62%, 62%, and 62% of the patients at 1, 3, 6, and 12 months after Tx, Two patients that had previously been transplanted exhibited a positive Lu screen result prior to re-Tx (see Table 4 patients 7 and 9). The median time to the detection of DSA was 24 months (range:
1-100).
In our cohort, a total of 110 biopsies were performed of which 56 showed signs of rejection, concerning 25 Txs, see Figure 2 . In relation to DSA status, the biopsy findings were as follows:
• 24 rejection-pos biopsies were from 13 Txs in which no DSA was detected during follow-up.
• 32 rejection-pos biopsies were from 12 Txs in which DSA occurred.
In eight biopsies (from eight Txs), DSA was detectable before the occurrence of rejection in the biopsy (25-0 days before); in four biopsies (from four Txs), DSA was detectable after the occurrence of rejection in the biopsy (1-26 days after); and in seven biopsies (from five Txs), no DSA was detectable more than 4 months before or 1 month after the occurrence of rejection in the biopsy. 
TA B L E 3 Baseline characteristics of the study population, rejection-pos and rejection-neg patients in 36 transplantations
• No DSA was tested around 13 rejection-pos biopsies (from nine Txs).
Out of 54 biopsies without rejection, DSA was present around three biopsies from three Txs.
Twelve of the 13 DSA-pos Txs (11/12 patients) in Table 4 showed rejection in biopsies and were treated for rejection. (In one Tx, no biopsy was performed thus not treated for rejection). In the 12 Txs, DSA fluctuations were evaluated during follow-up, see Figure 3 . A rejection-pos biopsy was treated with antirejection therapy.
• In nine Txs, DSA was detected 1 day to 46 months after antirejection therapy.
• In one Tx, DSA was detected 2 days after antirejection therapy. After a second antirejection therapy, no DSA was detected 46 months later.
• In one Tx, DSA was detected 3 months after therapy, spontaneously becoming negative 9 months later.
• In one Tx, no DSA was detected 7 months after first therapy, but DSA was detectable 5 months after consecutive therapy.
• In one Tx, DSA was not detected 3 and 8 years after the first antirejection therapy. DSA was detected 40 days after a consecutive antirejection therapy.
• In one Tx, no DSA was detected 28 days after antirejection therapy, but DSA was positive 6 months later, without additional antirejection therapy.
• In one Tx, DSA was detected 18 days before antirejection therapy, but DSA was not detectable 3.8 years later.
| Post-Tx outcomes
The mean GFR at baseline (1 month after Tx) in the Tx cohort was 79 ± 30 mL/min/1.73 m 2 , with no significant difference between the biopsy and non-biopsy group. The overall GFR decline over time is depicted in Figure 4 .
The mean last GFR was significantly lower in the biopsy group, compared to the non-biopsy group (mean GFR: 39.2 ± 21.6 vs 67.9 ± 22.6; P < 0.001). 
TA B L E 4 Characteristics of HLA DSAs in 13 Txs
F I G U R E 2 Flowchart biopsies
To analyze the difference between the biopsy and the nonbiopsy group, we used an outcome of 25% reduction in GFR for survival analysis, see Figure 5 . There was a significant difference for survival between the biopsy and the non-biopsy group (12 vs 84 months, respectively; P < 0.001). Patients with biopsy had a significantly shorter time to 25% GFR decline compared to patients without biopsy.
The primary outcomes for DSA included rejection, GFR decline of 25%, and last GFR. The mean last GFR was significantly lower in the rejection group, compared to the group without rejection (mean GFR: 36.2 ± 21.1 vs 53.5 ± 13.7; P = 0.018). The presence of DSA and rejection were significantly correlated in the Txs (P = 0.007). In the rejection group, 12 of 25 (48%) patients were DSA-pos, and in the non-rejection group, none of the patients developed DSA.
| D ISCUSS I ON
We conducted a retrospective study over a 10-year period for the presence of post-Tx donor-specific HLA antibodies, in 68 children who underwent 76 kidney Txs. The prevalence of DSAs was 19%, and the majority of these cases occurred in patients who underwent biopsy. This rate is similar to the prevalence in other reports on DSA Age at Tx was significantly older for patients who underwent biopsy, compared to patients who did not. This could be due to decreased adherence to immunosuppressive in older children. Another explanation might be a higher threshold for performing a biopsy in younger children, which necessitates general anesthesia.
The time to 25% GFR reduction from baseline was significantly shorter in patients who underwent biopsy, which was expected considering that biopsy was only performed on clinical indication. Morales-Buenrostro et al, 15 the prevalence of HLA antibodies was not related to a worse graft outcome. However, in this study samples
were not tested for DSA, and it is unclear whether HLA antibodies were pre-existent or occurred after Tx.
Gill et al 16 concluded that routine monitoring of HLA antibodies after Tx did not identify patients at risk before symptoms of rejection occurred. In our study, the detection of DSA before clinical signs of rejection was found in some but not all patients that received a biopsy.
In our cohort, biopsy was performed in 43 patients to detect rejection. Biopsy revealed rejection in all patients with DSA (two AMR, four TCMR, and six combined AMR and TCMR) and about half of the patients without DSA (one AMR, ten TCMR, and two combined AMR and TCMR). Thus, not all rejection occurs in the presence of DSAs, suggesting that HLA antibody screening alone is not sufficient to detect rejection.
This study has the following limitations. The analyses were performed retrospectively, using routinely collected serum samples after Tx, and using clinically indicated biopsies, when creatinine levels already had increased. Histological data, such as C4d staining,
were not available for all patients, as some biopsies were performed in a period in which C4d staining was not general practice in our investigated. As mentioned, humoral rejection leads to poorer outcome compared to cellular rejection. When a correlation between DSA and a certain rejection type would be found, more insight is gained into the effects of DSA on graft outcome. In our study, the small number of patients did not allow for a more thorough analysis of the specificities of HLA-DSA and the type of rejection.
We must take into consideration that not all HLA antibodies are directed against the graft. Normally, not all serum samples are tested for DSA. In our study, we tested all samples for DSA when the Lu screening assay was positive for HLA antibodies. Four of the 17 HLA antibody-positive patients had non-DSA-HLA antibodies. (Two of these patients received a transplant due to previous graft dysfunction). This illustrates that additional DSA testing is necessary when HLA antibodies are detected.
A clear association was found between DSA and rejection, but rejection can also occur in the absence of DSA. This underlines the necessity to investigate other markers for imminent rejection. As DSA is related to rejection, we may consider a biopsy when DSA is present, regardless of creatinine levels. However, evidence of a causal relation is lacking. Although performing protocol-based biopsies seems to reduce the risk of subclinical rejection, the yield of iterative biopsies needs to be evaluated.
In conclusion, our results emphasize the importance of serum sample testing for DSAs, especially when HLA antibodies are found after pediatric kidney Tx. In particular, in patients with a relatively high number of HLA mismatches, post-transplant DSA screening seems to be relevant. We recommend routine additional testing for DSA, when the Lu HLA antibody test is positive.
Future research with protocol-based biopsies, combined with HLA-DSA testing, will answer the question whether routine HLA antibody screening after renal Tx in children remains necessary.
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